ログイン

BLOOD BANKING

BLOOD BANKING
40問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Which of the following techniques uses restriction enzymes, electrophoresis, and then transfer of DNA fragments onto a solid matrix, followed by probing with labeled probes? a. Dot-blot b. Southern blot c. Western blot d. LCR

    b. Southern blot

  • 2

    The most serious HTRs are due to which incompatibility: a. ABO b. Rh c. MN d. Duffy

    a. ABO

  • 3

    What corrective action should be taken when rouleaux causes positive test results? a. Perform a saline replacement technique b. Perform an autoabsorption c. Run a panel d. Perform an elution

    a. Perform a saline replacement technique

  • 4

    A major crossmatch and screening cells are 2+ at IS, 1+ at 37°C, and negative at the IAT phase. Identify the most likely problem. a. Combination of antibodies b. Cold alloantibody c. Rouleaux d. Test error

    b. Cold alloantibody

  • 5

    An antibody screen is reactive at IAT phase of testing using a three-cell screen and the autocontrol is negative. What is a possible explanation for these results? a. A cold alloantibody b. High-frequency alloantibody or a mixture of alloantibodies c. A warm autoantibody d. A cold and warm alloantibody

    b. High-frequency alloantibody or a mixture of alloantibodies

  • 6

    All of the following are routinely performed on a cord blood sample except: a. Forward ABO typing b. Antibody screen c. Rh typing d. DAT

    b. Antibody screen

  • 7

    What ABO types may donate to any other ABO type? a. A negative, B negative, AB negative, O negative b. O negative c. A negative, B negative d. AB negative, A negative, B negative

    b. O negative

  • 8

    What should be done when a woman who is 24 weeks pregnant has a positive antibody screen? a. Perform an antibody identification panel; titer if necessary b. No need to do anything until 30 weeks gestation c. Administer Rh immune globulin (RhIg) d. Adsorb the antibody onto antigen-positive cells

    a. Perform an antibody identification panel; titer if necessary

  • 9

    The k (Cellano) antigen is ahigh-frequency antigen and is found on most RBCs. How often would one expect to find the corresponding antibody? a. Often b. Rarely c. Depends on the population d. Impossible to determine

    b. Rarely

  • 10

    What is the most common parasitic complication of transfusion? a. Babesia microti b. Trypanosoma cruzi c. Plasmodium species d. Toxoplasma gondii

    c. Plasmodium species

  • 11

    Blood serum of anti-A and anti-B is prepared from? a. AB b. O c. AB d. B

    b. O

  • 12

    Mother with cancer, gets blood from her daughter. What type of transfusion? a. Direct b. Apheresis c. Plasmapheresis d. Replacement

    a. Direct

  • 13

    Which of the following characteristically gives a refractile mixed-field appearance? a. Anti-K b. Anti-Dia c. Anti-Sda d. Anti-s

    c. Anti-Sda

  • 14

    Which of the following antigens has served as a useful tool in anthropologic studies of Mongolian ancestry? a. Dia b. Lea c. Xg d. Doa

    a. Dia

  • 15

    The prevalence of this antigen in Northern Europeans is 1% but is higher in the Mennonite population. a. Sc1 b. Sc2 c. Xg d. None of the above

    b. Sc2

  • 16

    A donor bag is half filled during donation when the blood flow stops. Select the correct course of action. a. Closely observe the bag for at least 3 minutes; if blood flow does not resume, withdraw the needle b. Remove the needle immediately and discontinue the donation c. Check and reposition the needle if necessary; if blood flow does not resume, withdraw the needle d. Withdraw the needle and perform a second venipuncture in the other arm

    c. Check and reposition the needle if necessary; if blood flow does not resume, withdraw the needle

  • 17

    AHG control cells: a. Positive control for anti-C3 reagents b. Only for IAT c. Coated only with IgG antibody d. Must be used to confirm all positive antiglobulin reactions.

    c. Coated only with IgG antibody

  • 18

    An EIA screening test for HTLV I/II was performed on a whole-blood donor. The results of the EIA were repeatedly reactive but the confirmatory test was negative. On the next donation, the screening test was negative by two different EIA tests. The donor should be: a. Accepted b. Deferred c. Told that only plasma can be made from his donation d. Told to come back in 6 months

    a. Accepted

  • 19

    Cryoprecipitate may be used to treat all of the following, except: a. von Willebrand’s disease b. Hypofibrinogenemia c. Idiopathic thrombocytopenic purpura (ITP) d. Factor XIII deficiency

    c. Idiopathic thrombocytopenic purpura (ITP)

  • 20

    A 10% red cell suspension in saline is used in a compatibility test. Which of the following would most likely occur? a. False-positive due to antigen excess b. False-positive due to prozone c. False-negative due to prozone d. False-negative due to antigen excess

    d. False-negative due to antigen excess

  • 21

    What is the component of choice for a patient with chronic granulomatous disease (CGD)? a. FFP b. Granulocytes c. Cryoprecipitate d. RBCs

    b. Granulocytes

  • 22

    What does a minor crossmatch consist of? a. Recipient plasma and recipient RBCs b. Recipient plasma and donor RBCs c. Recipient RBCs and donor plasma d. Donor plasma and donor RBCs

    c. Recipient RBCs and donor plasma

  • 23

    SITUATION: A cancer patient recently developed a severe infection. The patient’s hemoglobin is 8 g/dL owing to chemotherapy with a drug known to cause bone marrow depression and immunodeficiency. Which blood products are indicated for this patient? a. Liquid plasma and cryoprecipitate b. Crossmatched platelets and washed RBCs c. Factor IX concentrates and FFP d. Irradiated RBCs, platelets, and granulocytes

    d. Irradiated RBCs, platelets, and granulocytes

  • 24

    When may an IS crossmatch be performed? a. When a patient is being massively transfused b. When there is no history of antibodies and the current antibody screen is negative c. When blood is being emergency released d. When a patient has not been transfused in the past 3 months

    b. When there is no history of antibodies and the current antibody screen is negative

  • 25

    You CANNOT take aspirin for _____ before you donate platelets, because aspirin reduces the potency and performance of your platelets. a. 24 hours b. 48 hours c. 14 days d. 21 days

    b. 48 hours

  • 26

    Cryoprecipitate must be transfused within what period of time following thawing and pooling? a. 4 hours b. 8 hours c. 12 hours d. 24 hours

    a. 4 hours

  • 27

    Which drug can cause PERMANENT DEFERRAL? a. Soriatane b. Avodart c. Propecia d. Tegison

    d. Tegison

  • 28

    Which of the following is not a requirement for the electronic crossmatch? a. The computer system contains logic to prevent assignment and release of ABO incompatible blood b. There are concordant results of at least two determinations of the recipient’s ABO type on record, one of which is from the current sample c. Critical elements of the system have been validated on site d. There are concordant results of at least one determination of the recipient’s ABO type on file

    d. There are concordant results of at least one determination of the recipient’s ABO type on file

  • 29

    Reagent used to detect Rh antibodies except: a. IgM anti-D b. Anti-D c. IgE anti-D d. IgG anti-D

    c. IgE anti-D

  • 30

    How is an individual with genotype Dce/dce classified? a. Rh positive b. Rh negative c. Rhnull d. Total Rh

    a. Rh positive

  • 31

    If a patient has a positive direct antiglobulin test, should you perform a weak D test on the cells? a. No, the cells are already coated with antibody b. No, the cells are Rhnull c. Yes, the immunoglobulin will not interfere with the test d. Yes, Rh reagents are enhanced in protein media

    a. No, the cells are already coated with antibody

  • 32

    All of the following are reasons for performing an adsorption, except: a. Separation of mixtures of antibodies b. Removal of interfering substances c. Confirmation of weak antigens on RBCs d. Identification of antibodies causing a positive DAT

    d. Identification of antibodies causing a positive DAT

  • 33

    Which blood group has the least amount of H antigen? A. A1B B. A2 C. B D. A1

    A. A1B

  • 34

    What can be done if HDFN is caused by maternal anti-K? a. Give Kell immune globulin b. Monitor the mother’s antibody level c. Prevent formation of K-positive cells in the fetus d. Not a problem; anti-K not known to cause HDFN

    b. Monitor the mother’s antibody level

  • 35

    ISBT number 30: a. John Milton Hagen b. Globoside c. Gill d. Rh-associated glycoprotein (RhAG)

    d. Rh-associated glycoprotein (RhAG)

  • 36

    Which situation is not a cause of indefinite or permanent deferral of a donor? a. History of Creutzfeld-Jacob disease b. Male currently on Tegison. c. Donor tested reactive for HBV by nucleic acid testing (NAT) d. Accidental needlestick 1 year ago; negative for infectious disease.

    d. Accidental needlestick 1 year ago; negative for infectious disease.

  • 37

    Which vaccination does not need deferral? a. HPV b. Varicella c. Measles d. Smallpox

    a. HPV

  • 38

    Vaccination for MMR would result in a temporary deferral for: a. 4 weeks b. 2 weeks c. 8 weeks d. 16 weeks

    c. 8 weeks

  • 39

    Who is the best candidate for a predeposit autologous donation? a. A 45-year-old man who is having elective surgery in 2 weeks; he has alloanti-k b. A 23-year-old female leukemia patient with a hemoglobin of 10 g/dL c. A 12-year-old boy who has hemophilia d. A 53-year-old woman who has septicemia

    a. A 45-year-old man who is having elective surgery in 2 weeks; he has alloanti-k

  • 40

    CPDA-1 prolongs shelf life by: a. 21 days b. 35 days c. 42 days d. 2 days

    b. 35 days

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Which of the following techniques uses restriction enzymes, electrophoresis, and then transfer of DNA fragments onto a solid matrix, followed by probing with labeled probes? a. Dot-blot b. Southern blot c. Western blot d. LCR

    b. Southern blot

  • 2

    The most serious HTRs are due to which incompatibility: a. ABO b. Rh c. MN d. Duffy

    a. ABO

  • 3

    What corrective action should be taken when rouleaux causes positive test results? a. Perform a saline replacement technique b. Perform an autoabsorption c. Run a panel d. Perform an elution

    a. Perform a saline replacement technique

  • 4

    A major crossmatch and screening cells are 2+ at IS, 1+ at 37°C, and negative at the IAT phase. Identify the most likely problem. a. Combination of antibodies b. Cold alloantibody c. Rouleaux d. Test error

    b. Cold alloantibody

  • 5

    An antibody screen is reactive at IAT phase of testing using a three-cell screen and the autocontrol is negative. What is a possible explanation for these results? a. A cold alloantibody b. High-frequency alloantibody or a mixture of alloantibodies c. A warm autoantibody d. A cold and warm alloantibody

    b. High-frequency alloantibody or a mixture of alloantibodies

  • 6

    All of the following are routinely performed on a cord blood sample except: a. Forward ABO typing b. Antibody screen c. Rh typing d. DAT

    b. Antibody screen

  • 7

    What ABO types may donate to any other ABO type? a. A negative, B negative, AB negative, O negative b. O negative c. A negative, B negative d. AB negative, A negative, B negative

    b. O negative

  • 8

    What should be done when a woman who is 24 weeks pregnant has a positive antibody screen? a. Perform an antibody identification panel; titer if necessary b. No need to do anything until 30 weeks gestation c. Administer Rh immune globulin (RhIg) d. Adsorb the antibody onto antigen-positive cells

    a. Perform an antibody identification panel; titer if necessary

  • 9

    The k (Cellano) antigen is ahigh-frequency antigen and is found on most RBCs. How often would one expect to find the corresponding antibody? a. Often b. Rarely c. Depends on the population d. Impossible to determine

    b. Rarely

  • 10

    What is the most common parasitic complication of transfusion? a. Babesia microti b. Trypanosoma cruzi c. Plasmodium species d. Toxoplasma gondii

    c. Plasmodium species

  • 11

    Blood serum of anti-A and anti-B is prepared from? a. AB b. O c. AB d. B

    b. O

  • 12

    Mother with cancer, gets blood from her daughter. What type of transfusion? a. Direct b. Apheresis c. Plasmapheresis d. Replacement

    a. Direct

  • 13

    Which of the following characteristically gives a refractile mixed-field appearance? a. Anti-K b. Anti-Dia c. Anti-Sda d. Anti-s

    c. Anti-Sda

  • 14

    Which of the following antigens has served as a useful tool in anthropologic studies of Mongolian ancestry? a. Dia b. Lea c. Xg d. Doa

    a. Dia

  • 15

    The prevalence of this antigen in Northern Europeans is 1% but is higher in the Mennonite population. a. Sc1 b. Sc2 c. Xg d. None of the above

    b. Sc2

  • 16

    A donor bag is half filled during donation when the blood flow stops. Select the correct course of action. a. Closely observe the bag for at least 3 minutes; if blood flow does not resume, withdraw the needle b. Remove the needle immediately and discontinue the donation c. Check and reposition the needle if necessary; if blood flow does not resume, withdraw the needle d. Withdraw the needle and perform a second venipuncture in the other arm

    c. Check and reposition the needle if necessary; if blood flow does not resume, withdraw the needle

  • 17

    AHG control cells: a. Positive control for anti-C3 reagents b. Only for IAT c. Coated only with IgG antibody d. Must be used to confirm all positive antiglobulin reactions.

    c. Coated only with IgG antibody

  • 18

    An EIA screening test for HTLV I/II was performed on a whole-blood donor. The results of the EIA were repeatedly reactive but the confirmatory test was negative. On the next donation, the screening test was negative by two different EIA tests. The donor should be: a. Accepted b. Deferred c. Told that only plasma can be made from his donation d. Told to come back in 6 months

    a. Accepted

  • 19

    Cryoprecipitate may be used to treat all of the following, except: a. von Willebrand’s disease b. Hypofibrinogenemia c. Idiopathic thrombocytopenic purpura (ITP) d. Factor XIII deficiency

    c. Idiopathic thrombocytopenic purpura (ITP)

  • 20

    A 10% red cell suspension in saline is used in a compatibility test. Which of the following would most likely occur? a. False-positive due to antigen excess b. False-positive due to prozone c. False-negative due to prozone d. False-negative due to antigen excess

    d. False-negative due to antigen excess

  • 21

    What is the component of choice for a patient with chronic granulomatous disease (CGD)? a. FFP b. Granulocytes c. Cryoprecipitate d. RBCs

    b. Granulocytes

  • 22

    What does a minor crossmatch consist of? a. Recipient plasma and recipient RBCs b. Recipient plasma and donor RBCs c. Recipient RBCs and donor plasma d. Donor plasma and donor RBCs

    c. Recipient RBCs and donor plasma

  • 23

    SITUATION: A cancer patient recently developed a severe infection. The patient’s hemoglobin is 8 g/dL owing to chemotherapy with a drug known to cause bone marrow depression and immunodeficiency. Which blood products are indicated for this patient? a. Liquid plasma and cryoprecipitate b. Crossmatched platelets and washed RBCs c. Factor IX concentrates and FFP d. Irradiated RBCs, platelets, and granulocytes

    d. Irradiated RBCs, platelets, and granulocytes

  • 24

    When may an IS crossmatch be performed? a. When a patient is being massively transfused b. When there is no history of antibodies and the current antibody screen is negative c. When blood is being emergency released d. When a patient has not been transfused in the past 3 months

    b. When there is no history of antibodies and the current antibody screen is negative

  • 25

    You CANNOT take aspirin for _____ before you donate platelets, because aspirin reduces the potency and performance of your platelets. a. 24 hours b. 48 hours c. 14 days d. 21 days

    b. 48 hours

  • 26

    Cryoprecipitate must be transfused within what period of time following thawing and pooling? a. 4 hours b. 8 hours c. 12 hours d. 24 hours

    a. 4 hours

  • 27

    Which drug can cause PERMANENT DEFERRAL? a. Soriatane b. Avodart c. Propecia d. Tegison

    d. Tegison

  • 28

    Which of the following is not a requirement for the electronic crossmatch? a. The computer system contains logic to prevent assignment and release of ABO incompatible blood b. There are concordant results of at least two determinations of the recipient’s ABO type on record, one of which is from the current sample c. Critical elements of the system have been validated on site d. There are concordant results of at least one determination of the recipient’s ABO type on file

    d. There are concordant results of at least one determination of the recipient’s ABO type on file

  • 29

    Reagent used to detect Rh antibodies except: a. IgM anti-D b. Anti-D c. IgE anti-D d. IgG anti-D

    c. IgE anti-D

  • 30

    How is an individual with genotype Dce/dce classified? a. Rh positive b. Rh negative c. Rhnull d. Total Rh

    a. Rh positive

  • 31

    If a patient has a positive direct antiglobulin test, should you perform a weak D test on the cells? a. No, the cells are already coated with antibody b. No, the cells are Rhnull c. Yes, the immunoglobulin will not interfere with the test d. Yes, Rh reagents are enhanced in protein media

    a. No, the cells are already coated with antibody

  • 32

    All of the following are reasons for performing an adsorption, except: a. Separation of mixtures of antibodies b. Removal of interfering substances c. Confirmation of weak antigens on RBCs d. Identification of antibodies causing a positive DAT

    d. Identification of antibodies causing a positive DAT

  • 33

    Which blood group has the least amount of H antigen? A. A1B B. A2 C. B D. A1

    A. A1B

  • 34

    What can be done if HDFN is caused by maternal anti-K? a. Give Kell immune globulin b. Monitor the mother’s antibody level c. Prevent formation of K-positive cells in the fetus d. Not a problem; anti-K not known to cause HDFN

    b. Monitor the mother’s antibody level

  • 35

    ISBT number 30: a. John Milton Hagen b. Globoside c. Gill d. Rh-associated glycoprotein (RhAG)

    d. Rh-associated glycoprotein (RhAG)

  • 36

    Which situation is not a cause of indefinite or permanent deferral of a donor? a. History of Creutzfeld-Jacob disease b. Male currently on Tegison. c. Donor tested reactive for HBV by nucleic acid testing (NAT) d. Accidental needlestick 1 year ago; negative for infectious disease.

    d. Accidental needlestick 1 year ago; negative for infectious disease.

  • 37

    Which vaccination does not need deferral? a. HPV b. Varicella c. Measles d. Smallpox

    a. HPV

  • 38

    Vaccination for MMR would result in a temporary deferral for: a. 4 weeks b. 2 weeks c. 8 weeks d. 16 weeks

    c. 8 weeks

  • 39

    Who is the best candidate for a predeposit autologous donation? a. A 45-year-old man who is having elective surgery in 2 weeks; he has alloanti-k b. A 23-year-old female leukemia patient with a hemoglobin of 10 g/dL c. A 12-year-old boy who has hemophilia d. A 53-year-old woman who has septicemia

    a. A 45-year-old man who is having elective surgery in 2 weeks; he has alloanti-k

  • 40

    CPDA-1 prolongs shelf life by: a. 21 days b. 35 days c. 42 days d. 2 days

    b. 35 days